Activation of calcitonin gene-related peptide signaling through the prostaglandin E2-EP1/EP2/EP4 receptor pathway in synovium of knee osteoarthritis patients

Atsushi Minatani¹, Kentaro Uchida¹*, Gen Inoue¹, Shotaro Takano¹, Jun Aikawa¹, Masayuki Miyagi¹, Hisako Fujimaki¹, Dai Iwase¹, Kenji Onuma¹, Toshihide Matsumoto² and Masashi Takaso¹

Abstract

Background: Calcitonin gene-related peptide (CGRP) is a 37-amino-acid vasodilatory neuropeptide that binds to receptor activity-modifying protein 1 (RAMP1) and the calcitonin receptor-like receptor (CLR). Clinical and preclinical evidence suggests that CGRP is associated with hip and knee joint pain; however, the regulation mechanisms of CGRP/CGRP receptor signaling in synovial tissue are not fully understood.

Methods: Synovial tissues were harvested from 43 participants with radiographic knee osteoarthritis (OA; unilateral Kellgren/Lawrence (K/L) grades 3–4) during total knee arthroplasty. Correlations between the mRNA expression levels of CGRP and those of tumor necrosis factor-α (TNF-α), interleukin (IL)-1β, IL-6, and cyclooxygenase-2 (COX-2) were evaluated using real-time PCR analysis of total RNA extracted from the collected synovial tissues. To investigate the factors controlling the regulation of CGRP and CGRP receptor expression, cultured synovial cells were stimulated with TNF-α, IL-1β, IL-6, and prostaglandin E2 (PGE2) and were also treated with PGE2 receptor (EP) agonist.

Results: CGRP and COX-2 localized in the synovial lining layer. Expression of COX-2 positively correlated with CGRP mRNA expression in the synovial tissue of OA patients. The gene expression of CGRP and RAMP1 increased significantly in synovial cells exogenously treated with PGE2 compared to untreated control cells. In cultured synovial cells, CGRP gene expression increased significantly following EP4 agonist treatment, whereas RAMP1 gene expression increased significantly in the presence of exogenously added EP1 and EP2 agonists.

Conclusions: PGE2 appears to regulate CGRP/CGRP receptor signaling through the EP receptor in the synovium of knee OA patients.

Keywords: Knee osteoarthritis, Calcitonin gene-related peptide, Cyclooxygenase-2

* Correspondence: kuchida@med.kitasato-u.ac.jp
¹Department of Orthopedic Surgery, Kitasato University School of Medicine, 1-15-1 Minami-ku Kitasato, Sagamihara City, Kanagawa 252-0374, Japan
Full list of author information is available at the end of the article

© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
The main symptom of knee osteoarthritis (OA) is joint pain. Nonsteroidal anti-inflammatory drugs (NSAIDs) are the most widely used pharmaceuticals for treating OA [1]. Although NSAIDs are effective for reducing pain [2], drugs in this class are nephrotoxic and significantly increase the risk of gastrointestinal ulceration and bleeding and cardiovascular events [3]. For these reasons, the long-term use of NSAIDs is contraindicated in many OA patients, and a need therefore exists for the development of more effective and specific drugs for OA pain management.

Calcitonin gene-related peptide (CGRP) is a 37-amino-acid vasodilatory neuropeptide that binds to receptor activity-modifying protein 1 (RAMP1) and the calcitonin receptor-like receptor (CLR) [4]. Clinical and preclinical evidence suggests that CGRP is associated with hip and knee joint pain [5–14]. For example, CGRP-positive cells were immunohistochemically detected in the synovial tissue of OA patients [8, 11]. CGRP mRNA was also observed in the synovial tissue of developmental dysplasia of the hip patients [10], and the mRNA and protein expression of CLR and RAMP1 were detected in cultured synovial cells harvested from OA patients [5]. In addition, CGRP antagonist administration to rat OA models led to the relief of pain [6, 7]. Taken together, these observations suggest that CGRP/CGRP receptor signaling in synovial tissue plays an important role in OA pathology. However, the regulatory mechanisms of CGRP and its receptor in synovial tissue are not fully understood.

Here, we investigated the regulation of CGRP and the CGRP receptor in the synovium of 43 knee OA patients.

Methods
Reagents
Human recombinant interleukin-6 (IL-6), interleukin-1β (IL-1β), and tumor necrosis factor-α (TNFα) were purchased from Biolegend (San Diego, CA, USA). Prostaglandin E2 (PGE2) and butaprost (EP2 agonist) were purchased from Sigma (St. Louis, MO, USA). Iloprost (EP1 agonist), sulprostone (EP3 agonist), and CAY10598 (EP4 agonist) were purchased from Caymann (Ann Arbor, MI, USA).

Patients
A total of 43 participants with radiographic knee OA (unilateral Kellgren/Lawrence (K/L) grades 3–4) underwent total knee arthroplasty at our institution. The study included 9 men and 34 women aged 50–87 years (mean ± SD, 73.6 ± 8.7 years) with a mean ± SD body mass index (BMI) of 26.1 ± 3.9 kg/m² (range 20.3–36.7). The K/L grades of the 43 operated knees were comprised of 42 % grade 3 and 58 % grade 4. A sample of synovial tissue was harvested from each operated knee during the total knee arthroplasty surgery. A portion of each synovial tissue sample was fixed with 4 % paraformaldehyde formalin for 48 h for histological analysis, and the remaining sample was stored at –80 °C until used for RNA extraction for real-time PCR analysis. Synovial tissues from 12 patients were also used for cell culture. Informed consent for participation in this study was obtained from each patient on the day before surgery.

Immunohistochemistry
To determine the localization of CGRP and cyclooxygenase 2 (COX-2), the paraformaldehyde-fixed synovial tissues samples were embedded in paraffin and sliced into 3-µm-thick sections. Sections were immunohistochemically stained with rabbit polyclonal primary antibody against COX-2 (Abcam, Cambridge, MA) or mouse monoclonal primary antibody against CGRP (Abcam) using the streptavidin-biotin-peroxidase method (Histofine SAB-PO Kit; Nichirei, Tokyo, Japan).

Real-time PCR analysis
Total RNA was isolated from the harvested synovial tissue using TRIzol reagent (Invitrogen, Carlsbad, CA) following the manufacturer’s protocol. The extracted RNA was used as template for first-strand cDNA synthesis of CGRP, RAMP1, CLR, COX-2, TNF-α, IL-1β, and IL-6 using SuperScript III RT (Invitrogen) in reaction mixtures composed of 2 µL cDNA, 0.2 µM specific primer pair, 12.5 µL SYBR Premix Ex Taq (Takara, Kyoto, Japan), and nuclease-free water in a final volume of 25 µL. The primers were designed using Primer Blast software and were synthesized by Hokkaido System Science Co., Ltd. (Sapporo, Japan). The sequences of the PCR primer pairs are listed in Table 1. The specificity of the amplified products was examined by melt curve analysis. Quantitative PCR was performed using a Real-Time PCR Detection System (CFX-96; Bio-Rad, CA, USA) to determine relative mRNA expression levels. The PCR cycle parameters were as follows: 95 °C for 1 min, followed by 40 cycles of 95 °C for 5 s and 60 °C for 30 s. mRNA expression was normalized to the levels of GAPDH mRNA.

Synovial cell culture
To investigate the factors regulating CGRP and CGRP receptor expression, synovial cells were harvested from synovium collected from the knees of 12 OA patients. Mononuclear cells were isolated from synovium by digestion of the tissue with 40 ml of 0.1 % type I collagenase. The obtained cells were cultured in α-MEM in 6-well plates. After 7 days, the cells harvested from six patients were stimulated with human recombinant IL-6 (100 ng/ml), IL-1β (50 ng/ml), TNF-α (10 ng/ml), or
PGE2 (10 μM) for 24 h. The cells harvested from another six patients were stimulated with 10 μM iloprost, butaprost, sulprostone, or CAY10598 for 24 h. After the treatments, cells were harvested for RNA isolation, as described above, and CGRP, RAMP1, and CLR expression was analyzed by RT-PCR. Cells were also harvested for protein extraction, as described below, and RAMP1 protein expression was analyzed by Western blotting.

Western blotting
To investigate RAMP1 protein expression, cells harvested from five patients were stimulated with 10 μM PGE2, iloprost, butaprost, sulprostone, or CAY10598 for 24 h. Synovial cells were then lysed in RIPA buffer (Wako) supplemented with a protease inhibitor cocktail (Roche), and the protein concentration for each tissue extract was determined using the bicinchoninic acid (BCA) assay (Pierce, Rockford, IL, USA). Protein extracts (10 μg/lane) were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and were electrophoretically transferred onto polyvinyl difluoride membranes, which were then blocked with PVDF blocking reagent (Toyobo, Osaka, Japan) for 1 h. The blocked membranes were incubated overnight at 4 °C with rabbit monoclonal primary antibodies against RAMP1 (Abcam). The primary antibodies were diluted 1:1000 with Can Get Signal Solution 1 (Toyobo). The membranes were incubated overnight at 4 °C with rabbit secondary antibodies (GE Healthcare, NJ, USA) which were diluted 1:1000 with Can Get Signal Solution 2 (Toyobo). Immunoreactive proteins were visualized by chemiluminescence using ImmunoStar LD reagent (Wako, Tokyo, Japan), and images were captured using a LAS-5000 system (Fuji Film, Tokyo, Japan).

Statistical analysis
Pearson’s correlation coefficient was used to evaluate the relationship between CGRP and the examined stimulatory factors. A p value of <0.01 was considered statistically significant for the correlation coefficient analysis. Differences between the untreated and treated synovial cells were compared using one-way ANOVA with Fisher’s least significant difference test. A p value of <0.05 was considered statistically significant. Cook’s distance statistical test was used to identify potential statistical outliers that influence the linear regression coefficient analysis. All statistical analyses were performed using SPSS software (v. 19.0; SPSS, Chicago, IL, USA).

Results
Relationship between CGRP, inflammatory cytokines, and COX-2 expression levels in synovial tissue of OA patients
Seven synovial tissue samples had seven outliers (two for IL-6 and five for IL-1B), which were excluded from the analysis. The relationship between CGRP mRNA expression and the mRNA expression levels of several inflammatory factors in synovial tissue of OA patients was first examined. The expression levels of cyclooxygenase 2 (COX-2) were positively correlated with those CGRP, whereas no correlation between the mRNA expression levels of IL-6, IL-1β, or TNF-α and those of CGRP were detected in the synovial tissue (Fig. 1).

Localization of COX-2 and CGRP in synovial tissue of OA patients
As real-time PCR analysis detected a correlation between CGRP and COX-2 mRNA expression, immunohistochemical analysis was performed to investigate the localization of CGRP and COX-2. The analysis revealed that both COX-2 and CGRP protein localized in the synovial lining layer (Fig. 2).

Effect of inflammatory cytokines and PGE2 on CGRP expression in cultured synovial cells
The effects of inflammatory cytokines and PGE2 on the mRNA expression of CGRP and its associated receptors in synovial tissue of the knee OA patients were next examined. As TNF-α and IL-1β stimulate CGRP expression in several cell lines in vitro [15, 16], these inflammatory cytokines were used as positive controls. Real-time PCR analysis revealed that the gene expression of CGRP increased significantly in synovial cells in the presence of exogenously added TNF-α, IL-1β, and PGE2 compared to untreated control cells, but was not affected in IL-6-treated synovial cells (Fig. 3a). RAMP1 expression increased upon PGE2 stimulation, but remained
relatively unchanged in cells treated with TNF-α, IL-1β, and IL-6 (Fig. 3b). No marked differences in CLR expression were detected among the stimulated and untreated synovial cells for any of the examined factors (Fig. 3c).

**Effect of EP1-4 agonists on CGRP and CGRP receptor expression in cultured synovial cells**

PGE2 acts via four different receptor subtypes: EP1, EP2, EP3, and EP4. Next, the regulation of CGRP and RAMP1 by EPs was investigated using EP1-4 agonists. Real-time PCR analysis revealed that the gene expression of CGRP increased significantly in synovial cells in the presence of exogenously added EP4 agonist compared to untreated control cells (Fig. 4a). The expression of CGRP was not affected in EP1, EP2, and EP3 agonist-treated synovial cells (Fig. 4a). In addition, RAMP1 mRNA expression and protein levels increased significantly in synovial cells treated with exogenously added EP1 and EP2 agonists compared to untreated control cells, but was not affected in EP3 or EP4 agonist-treated synovial cells (Figs. 4b and 5). No differences in CLR expression were detected between the untreated and agonist-treated cells (Fig. 4c).

**Discussion**

In the present study investigating the mechanisms underlying the regulation of CGRP in the synovial tissue of knee OA patients, a correlation between CGRP and COX-2 expression was detected, and both CGRP and COX-2 localized in the synovial lining layer. In addition, the treatment of synovial fibroblast cultures with PGE2 and EP4 agonist also stimulated CGRP expression, and
PGE2, EP1, and EP2 agonist stimulated RAMP1 expression. Taken together, these findings suggest that the PGE2/EP signaling pathway regulates CGRP/CGRP receptor signaling in synovial fibroblasts.

Recent behavioral studies have reported that CGRP/CGRP receptor signaling is regulated by inflammatory cytokines, growth factors, and PGE2 in neural cells [15, 17], epithelial cells [16], and immune cells [18–20]. In trigeminal ganglion neurons, IL-1β and TNF-α induced CGRP release in [15, 16], and IL-1β additionally promoted COX-2 and PGE2 synthesis, resulting in elevated CGRP release [17]. Liu et al. [16] reported that IL-1β also stimulates CGRP release from human type II alveolar epithelial cells [16]. In the present study, COX-2 expression positively correlated with that of CGRP in synovial tissue, and PGE2, which is the enzymatic product of COX-2, also stimulated CGRP gene expression. In contrast, exogenously added TNF-α and IL-1β stimulated CGRP expression in vitro, but no significant correlation was detected between TNF-α- or IL-1β-induced CGRP mRNA expression levels in the synovial tissue from knee joints of OA patients. In a recent study, Nakata et al. [21] demonstrated that cyclic compressive loading on a 3D-cultured construct of human synovial fibroblasts upregulated PGE2 and COX-2 in the absence of IL-1β or TNF-α stimulation. These results suggest that CGRP may be regulated by PGE2 in an IL-1β- and TNF-α-independent manner in the synovium of OA patients.

RAMP1 is required for the translocation of CLR to the cell surface and also participates in ligand binding and is therefore essential for CGRP receptor signaling [22, 23]. Consistent with these properties, the overexpression of RAMP1 sensitizes vascular smooth muscle cells and trigeminal ganglia neurons to CGRP. A recent study reported that RAMP1 mRNA expression was detected in synovial cell culture isolated from OA patients [5]; however, the underlying regulatory mechanisms controlling this expression were not elucidated. Here, we also detected RAMP1 expression in cultured synovial cells and found that PGE2 regulated not only CGRP expression but also that of the RAMP1 in synovial cells.

PGE2, which is a major pro-inflammatory prostanooid and plays a role in nociceptive processing, acts via four different G-protein-coupled receptor subtypes: EP1, EP2, EP3, and EP4 [24, 25]. EP1 receptors are involved in mechanical sensitization at the spinal cord level. Intrathecal injection of the EP1-selective antagonist ONO-8711 in the carrageenan model of inflammatory pain and oral administration of ONO-8711 in a model of postoperative pain improved mechanical hyperalgesia.
The EP2 receptor also contributes to spinal pain sensitization during inflammatory pain states [28, 29]. Furthermore, increased levels of PGE2 upregulates expression of the EP4 receptor subtype in rat sensory dorsal root ganglion (DRG) neurons [30]. Southall et al. [31] reported that the sensitization of sensory neurons is mediated mainly through EP4 receptors and does not proceed via EP3 receptors. Here, we found that the treatment of synovial cell cultures with EP4 agonist led to increased CGRP expression and that the exogenous addition of EP1 and EP2 agonists increased RAMP1 expression. Based on the findings of these previous and present studies, PGE2 appears to regulate CGRP/CGRP receptor signaling through differential EP receptors in the synovium of knee OA patients.

A number of clinical trials have demonstrated that CGRP and CGRP receptor antagonists are efficacious for migraine treatment [32–35]. In addition, humanized antibody against CGRP (LY295174) relieved pain in a rat OA model [6, 7], and clinical trials of anti-CGRP antibody in human OA patients are underway [36]. In the present study, although the relationship between CGRP expression levels and pain in OA patients was not determined, our findings related to CGRP and CGRP receptor regulation in synovial tissue may provide valuable information for developing future pain treatments for OA.

Several limitations of the present study warrant mention. First, the lack of inclusion of a control, non-osteoarthritic patient population is needed to confirm whether CGRP levels are elevated in the synovial tissues of OA patients as compared to non-OA patients. Second, it remains to be determined if the elevation of CGRP levels contributes to OA pain. Third, CGRP mRNA expression and localization of CGRP was examined using real-time PCR and immunohistochemistry, respectively; however CGRP protein concentration was not determined in the synovial tissue or cell culture supernatant. Finally, the effects of CGRP on synovial cells were not evaluated.

**Conclusions**

In conclusion, CGRP/CGRP receptor signaling in synovial tissue of OA patients is regulated by PGE2 and PGE2 receptor signaling. The findings presented here may provide useful information for developing therapeutic strategies for managing OA pain.

**Abbreviations**

CGRP: Calcitonin gene-related peptide; CLR: Calcitonin receptor-like receptor; COX-2: Cyclooxygenase 2; IL-1β: Interleukin-1β; IL-6: Interleukin-6; NSAIDs: Nonsteroidal anti-inflammatory drugs; OA: Osteoarthritis; PGE2: Prostaglandin E2; RAMP1: Receptor activity-modifying protein 1; TNFα: Tumor necrosis factor-α

**Acknowledgements**

We thank Ms. Yuko Onuki for her assistance in the statistical analysis of the data in this study.

**Funding**

This investigation was supported in part by JSPS KAKENHI Grant no. 15K20016, the Uehara Memorial Foundation, a Kitasato University Research Grant for Young Researchers, and research grants from the Parents’ Association of Kitasato University School of Medicine.

**Availability of data and materials**

The datasets supporting the conclusions of this article are included within the article.

**Authors’ contributions**

KU, GI, and MT designed the study and performed the analysis of the data. AM and KU wrote the manuscript. AM, ST, JA, MM, HF, DI, KO, and TM participate in the data collection. All authors read and approved the final manuscript.

**Competing interests**

The authors declare that they have no competing interests.

**Consent for publication**

Not applicable.

**Ethics approval and consent to participate**

This study was approved by the Ethics Review Board of Kitasato University (reference number: KMEO B13-113). Consent to participate was obtained from the participants for the harvesting of their synovial tissue for use in this study.

**Author details**

1Department of Orthopedic Surgery, Kitasato University School of Medicine, 1-15-1 Minami-ku Kitasato, Sagamihara City, Kanagawa 252-0374, Japan.

2Department of Pathology, Kitasato University School of Medicine, 1-15-1 Minami-ku Kitasato, Sagamihara City, Kanagawa 252-0374, Japan.

**Received**: 16 June 2016 **Accepted**: 28 September 2016 **Published online**: 17 October 2016

**References**

1. Jozwiak-Bebenista M, Nowak IZ. Paracetamol: mechanism of action, applications and safety concern. Acta Pol Pharm. 2014;71:11–23.
20. Bracci-Laudiero L, Aloe L, Caroleo MC, Buanne P, Costa N, Starace G, Wells G. Acetaminophen for osteoarthritis. Cochrane Database Syst Rev. 2006;1:CD004257.

19. Ma W, Dumont Y, Vercauteren F, Quirion R. Lipopolysaccharide induces interleukin-1beta induces beta-calcitonin. Clin Orthop Relat Res. 2014;472:10.

18. Li W, Hou L, Zang S, Interleukin-1beta induces beta-calcitonin gene-related peptide secretion in human type II alveolar epithelial cells. FASEB J. 2008;22:1603–5.

17. Neelb L, Bell L, Bell K, Hof M, Hoffner H, Dornal U, Reuter U. IL-1beta stimulates COX-2 dependent PGE2 synthesis and GPRC release in rat trigrermen ganglia cells. PLoS One. 2011;6:e17360.

16. Bracci-Laudiero L, Aloe L, Buonacc R, Aloe L, Caroleo MC, Buanne P, Costa N, Starace G. Endogenous NGF regulates CGRP expression in human monocytes, and affects HLA-DR and CD86 expression and IL-10 production. Blood. 2005;106:3507–14.

15. Shimomura K, Kanamoto T, Kita K, Akamine Y, Nakamura N, Mae T, Yoshikawa H, Nakata K. Cyclic compressive loading on 3D tissue of human synovial fibroblasts upregulates prostaglandin E2 via COX-2 production without IL-1beta and TNF-alpha. Bone Joint Res. 2014;3:280–8.

14. Q, T, Hay DL. Structure-function relationships of the N-terminus of receptor activity-modifying proteins. Br J Pharmacol. 2010;159:1059–68.

13. Machtui AM, Fraser NJ, Main MJ, Wise A, Brown J, Thompson N, Solari R. Lee MG, Fool DW, RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature. 1998;393:333–9.

12. Nakamura N, Sugimoto Y, Ishikuzi F, Prostanoid receptors: structures, properties, and functions. Physiol Rev. 1999;79:1193–236.

11. Coleman RA, Smith WL, Narumiya S. International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol Rev. 1994;46:205–29.

10. Kawahara H, Sakamoto A, Takeda S, Onodera I, Imaki I, Ogawa R, A prostaglandin E2 receptor subtype EP1 receptor antagonist (ONO-8711) reduces hyperalgesia, allodynia, and c-fos gene expression in rats with chronic nerve constriction. Anesth Analg. 2001;93:1012–7.

9. Nakayama Y, Orito K, Namiki A. Role of prostaglandin receptor EP1 in the spinal dorsal horn in carrageenan-induced inflammatory pain. Anesthesiology. 2002;97:1254–64.

8. Harvey R, Depner UB, Wasse H, Ahmad S, Heinrich C, Reinhold H, Smart T, Harvey K, Schutz B, Bo-Salem OM, Zimmer A, Poisbeau P, Wenz H, Wolf C, Gasser C, Meier U, Pollant S, Betz H, Zeilhofer HU, Muller U. GlyR alpha3: an essential target for spinal PGE2-mediated inflammatory pain sensitization. Science. 2004;304:884–8.

7. Reinhold H, Ahmad S, Depner UB, Lakh B, Heinrich C, Hamza M, Pahl A, Brune K, Narumiya S, Muller U, Zeilhofer HU. Spinal inflammatory hyperalgesia is mediated by prostaglandin E receptors of the EP2 subtype. J Clin Invest. 2005;115:5673–9.

6. Lin CR, Amaya F, Barrett L, Wang H, Takada J, Samaa TA, Woff CC. Prostaglandin E2 receptor EP4 contributes to inflammatory pain hypersensitivity. J Exp Pharmacol. 2006;319:1096–103.

5. Southall M, Vasko M. Prostaglandin receptor subtypes, EP3, EP4, mediate the prostaglandin E2-induced cAMP production and sensitization of sensory neurons. J Biol Chem. 2001;276:16083-91.

4. Bigal ME, Walter S, Rapoport AM, Therapeutic antibodies against CGRP or its receptor. Br J Clin Pharmacol. 2015;79:988–95.

3. Hewitt DJ, Aurora SK, Dieck DW, Goddard PJ, Ge YJ, Bachman R, Tanafori D, Fan X, Assaid C, Lines C, Ho TW. Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine. Cephalalgia. 2011;31:722–32.

2. Ho TW, Ferrari MD, Ge YJ, Bachman R, Tanafori D, Fan X, Assaid C, Lines C, Ho TW. Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine. Cephalalgia. 2011;31:722–32.

1. Von TW, Ferrari MD, Dieck DW, Goddard PJ, Ge YJ, Bachman R, Tanafori D, Fan X, Assaid C, Lines C, Ho TW. Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine. Cephalalgia. 2011;31:722–32.